GlassScriptPhysician profile
Deborah D Mccoy
NPI 1649387002
$4,307.68
in general payments reported to CMS, 2019-2025
30 companies · $1,396 in 2025
The $1,396 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $21.11 · 2021: $125 · 2022: $695 · 2023: $903 · 2024: $1,168 · 2025: $1,396.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,467.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,466.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $446.82 | 2022-2025 | |
| Amgen INC. | $440.70 | 2022-2025 | Krystexxa, Tavneos |
| Akebia Therapeutics INC | $437.69 | 2021-2025 | Vafseo, Auryxia |
| Otsuka America Pharmaceutical, INC. | $403.42 | 2022-2025 | Jynarque, Voyxact |
| Lilly USA, LLC | $367.61 | 2021-2024 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $356.19 | 2022-2025 | Farxiga, Lokelma |
| Ani Pharmaceuticals, INC. | $235.15 | 2022-2025 | Purified Cortrophin Gel |
| Vifor Pharma, INC. | $214.36 | 2021-2023 | Veltassa |
| Novo Nordisk INC | $205.28 | 2024-2025 | Ozempic, Rybelsus |
| Aurinia Pharma U.S., INC. | $168.54 | 2022-2024 | Lupkynis |
| Mallinckrodt Hospital Products INC. | $138.26 | 2023-2025 | Acthar, Terlivaz |
| Horizon Therapeutics Plc | $124.99 | 2023 | Krystexxa |
| Opko Pharmaceuticals, LLC | $123.05 | 2022-2025 | Rayaldee |
| Ardelyx, INC. | $86.89 | 2024-2025 | Ibsrela |
| Boehringer Ingelheim Pharmaceuticals, INC. | $78.15 | 2024-2025 | Jardiance |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scpharmaceuticals INC. | $75.40 | 2025 | |
| Calliditas Therapeutics US INC. | $71.44 | 2022-2023 | Tarpeyo |
| Apellis Pharmaceuticals, INC. | $56.85 | 2025 | Empaveli |
| Pharmacosmos Therapeutics INC. | $41.38 | 2022 | |
| Travere Therapeutics, INC. | $31.87 | 2022 | |
| Inspire Medical Systems, INC. | $27.30 | 2025 | Inspire |
| Merck Sharp & Dohme LLC | $25.58 | 2025 | Prevymis |
| Pfizer INC. | $22.80 | 2023 | |
| Ibsa Pharma INC. | $22.58 | 2024 | Licart, Tirosint |
| Janssen Pharmaceuticals, INC | $21.11 | 2019 | |
| Cormedix INC. | $20.24 | 2025 | Defencath |
| Glaxosmithkline, LLC. | $17.64 | 2025 | Shingrix, Arexvy |
| Takeda Pharmaceuticals U.S.A., INC. | $17.08 | 2023 | Gattex |
| Currax Pharmaceuticals LLC | $15.21 | 2024 | Contrave |
| Novartis Pharmaceuticals Corporation | $14.10 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deborah Mccoy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.